TD Cowen Maintains Buy on LENZ Therapeutics, Lowers Price Target to $50

Benzinga · 1d ago
TD Cowen analyst Stacy Ku maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $60 to $50.